Diabetic nephropathy (DN) is a major driver of chronic kidney disease, yet preclinical models often fail to replicate human disease severity. GemPharmatech addresses this by developing an improved translational DN mouse model that mimics progressive human kidney damage—enabling better evaluation of future therapies.